Bioanalytical Strategies That Accelerate The Development Of Assays For Insulin Analogs And Other Large Peptides

Quantifying insulin analogues and other large peptides plays an important part in improving the outcome of downstream formulation development and clinical trial activities. However, this growing class of biotherapeutics is known to present sensitivity challenges when trying to measure trace levels of these types of compounds, thus requiring advanced technologies such as 2D ultra-performance liquid chromatography-mass spectrometry (LC-MS).

Learn how a physicochemical-based approach can help to accelerate the development of bioanalytical assays for insulin analogues, avoiding delays and increasing efficiency in clinical trial processes.